Publisher
Springer Science and Business Media LLC
Subject
Molecular Biology,Applied Microbiology and Biotechnology,Biochemistry,General Medicine,Bioengineering,Biotechnology
Reference19 articles.
1. Lister, P. D., & Wolter, D. J. (2005). Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa. Clinical Infectious Diseases, 40(Suppl 2), S105–S114.
2. Chiong, F., Wasef, M. S., Liew, K. C., Cowan, R., Tsai, D., Lee, Y. P., Croft, L., Harris, O., Gwini, S. M., & Athan, E. (2021). The impact of infectious diseases consultation on the management and outcomes of Pseudomonas aeruginosa bacteraemia in adults: A retrospective cohort study. BMC Infectious Diseases, 21(1), 671.
3. Tian, H. L., Shi, W., Zhou, H. F., Yuan, L., Yao, K. H., Rexiati, D., & Xu, A. M. (2018). Serotype distribution and drug resistance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated from nasopharynx of Uygur children. Chinese Journal of Pediatrics, 56(4), 279–283. (In Chinese).
4. Hirabayashi, A., Kato, D., Tomita, Y., Iguchi, M., Yamada, K., Kouyama, Y., Morioka, H., Tetsuka, N., & Yagi, T. (2017). Risk factors for and role of OprD protein in increasing minimal inhibitory concentrations of carbapenems in clinical isolates of Pseudomonas aeruginosa. Journal of Medical Microbiology, 66(11), 1562–1572.
5. Purssell, A., & Poole, K. (2013). Functional characterization of the NfxB repressor of the mexCD-oprJ multidrug efflux operon of Pseudomonas aeruginosa. Microbiology, 159(Pt 10), 2058–2073.